Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00983957 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
A Phase 1 study of Chronic Hepatitis C, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 3
- Study locations
NCT00983957 is a Phase 1 study of Chronic Hepatitis C that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 47 participants, below the 211-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00983957, a Phase 1 study of Chronic Hepatitis C, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess the effect of BMS-790052 on the pharmacokinetics of Ortho Tri-Cyclen® in healthy female subjects.
Conditions Studied
Interventions
- DRUG BMS-790052
- DRUG Ortho Tri-Cyclen®
Study Locations (3)
Arizona
- MDS Pharma Services (US), Inc - Tempe
Texas
- Covance Clinical Research Unit, Inc. - Austin
Quebec
- Local Institution - Saint-Laurent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00983957
The ClinicalTrials.gov registry entry for NCT00983957 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 211-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (78% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which BMS-790052 is the first listed.
NCT00983957 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Texas, Quebec.
Frequently Asked Questions
What is clinical trial NCT00983957 about?
NCT00983957 is a clinical study titled "Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects". The purpose of this study is to assess the effect of BMS-790052 on the pharmacokinetics of Ortho Tri-Cyclen® in healthy female subjects.
What is the current status of trial NCT00983957?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2009-10. Estimated completion is 2010-02.
What conditions does trial NCT00983957 study?
This clinical trial studies the following conditions: Chronic Hepatitis C.
What interventions are being tested in trial NCT00983957?
The interventions under investigation include: BMS-790052 (DRUG), Ortho Tri-Cyclen® (DRUG).
Who is sponsoring clinical trial NCT00983957?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00983957 being conducted?
This trial has 3 study locations across Arizona, Texas, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance
COMPLETED · Phase 1
-
A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
COMPLETED · Phase 1
-
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
COMPLETED · Phase 1
-
Q-Trial in Patients With Hepatitis C
COMPLETED · Phase 1
-
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
COMPLETED
-
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.